Navigation Links
Grant for brain tumor and deafness research
Date:7/27/2009

Researchers at the Peninsula Medical School have received a grant of over 39,000 from the charity Deafness Research UK, to investigate the role of brain tumours causing deafness in children and adults and the development of therapies using in vitro models.

These tumours and a variety of other tumours are caused by mutations affecting a protein called merlin, which in turn cause cancers in a range of cell types including Schwann cells in the nervous system. Schwann cells produce the sheaths that surround and insulate neurons.

Although the tumours are benign, they are frequent. They can be inherited and come in numbers. The sheer number of them can overwhelm a patient, often leading to deafness and eventually to death. Patients can suffer from 20 to 30 tumours at any one time, and the condition typically affects older children and young adults.

No therapy, other than invasive surgery aiming at a single tumour and which may not eradicate the full extent of the tumours, exists. The hereditary condition affects one in every 2,500 people worldwide. It can affect any family, regardless of past history, through gene mutation and currently there is no cure.

In some cases, pressure from the tumours affect the process of hearing leading to hearing loss or total deafness. The research will use a human acoustic neuroma in vitro model to identify how and why the tumours grow and eventually lead to hearing damage, and to test drug-based therapies designed to alleviate the problem.

The research is led by Professor Oliver Hanemann, Chair of Clinical Neurobiology at the Peninsula Medical School. He said: "We have already achieved some success in re-profiling an existing drug called sorafenib by using the human in-cell model. The re-profiled drug has a positive affect on multiple brain tumours. As a consequence, we can go straight to clinical trials and introduce therapies to patients sooner rather than later using sorafenib or simila
'/>"/>

Contact: Andrew Gould
andrew.gould@pms.ac.uk
The Peninsula College of Medicine and Dentistry
Source:Eurekalert

Page: 1 2

Related medicine news :

1. UVa researcher awarded $3.6 million grant to fight drug-resistant bacteria
2. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
3. $21.8 Million NIH Grant for Fragile X Research
4. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
5. Boston University School of Medicine researcher recipient of Memory Ride Grant
6. RAND researchers offer options to improve immigrant health care quality, access
7. Pennsylvania Department of Aging Receives Grant to Improve Alzheimers Support
8. CAS Medical Systems, Inc. Awarded $2.8 Million Grant by National Institutes of Health
9. NIH awards Einstein multimillion dollar grant to extend studies of exceptional longevity
10. Johns Hopkins receives $100 million grant to speed research from clinic to community
11. Major grant advances UWs clinical and translational research enterprise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , ... July 31, 2015 , ... ... industry players to know in predictive health analytics , Jvion continues to ... The firm creates predictive software that targets patient and population level illness to ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... important workshop at its new True North Conference Center. The medical community, social ... the Jacksonville community may be more aligned in the effort to better understand ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... According to the article published ... of the Pasadena courthouse was contained and extinguished by the city’s fire department before it ... the building at the time of the fire, and it was a fire alarm system ...
(Date:7/31/2015)... , ... July 31, 2015 , ... As part of ... community involvement and support of animal welfare organizations is essential to the longevity of ... consecutive year in the National Association of Professional Pet Sitters (NAPPS) annual Presents 4 ...
(Date:7/31/2015)... ... July 31, 2015 , ... Girl Scouts of Historic Georgia and ... through the Girl Scout "Be a Friend First" program. Representatives from Peach State Health ... , “Peach State Health Plan and our parent company, Centene Corporation, are dedicated to ...
Breaking Medicine News(10 mins):Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 3Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 2Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 3Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 4Health News:Peach State Health Plan Presents $10,000 Check for “Be a Friend First” Anti-Bullying Program to Local Girl Scouts 2
... researchers from King's College London has revealed that more than ... to die at home, but of them are unable to ... injection of funds, end of life programmes still lack proper ... Medical Journal. ,Lead researcher Professor Irene ...
... about the goodness of Vitamin E is about to receive ... Ohio State University who studied how two forms of vitamin ... the hypothesis. ,In the past couple of decades, benefits ... Most of it in the favour while some say that ...
... molecular map and other similar discoveries that could combat ... population//. ,'The inroads can give doctors the ... Soo Khee Chee, director of the National Cancer Centre ... included experts from the University of Hong Kong, University ...
... been known for a long time that mutual antagonism between ... disease//. It has now been possible to pinpoint the exact ... hardening of coronary arteries (atherosclerosis) in women while controlling behavior ... disease in men. ,Dr. Tim Smith and fellow ...
... study done to analyze the health benefits of anti-oxidants, ... a double-edged sword//. ,Everyday, a number of ... of consuming anti-oxidants. This study has warned that under ... lead to increased risk for development of cardiovascular disease, ...
... High Court would pass judgment regarding an appeal by health ... let a 17-month-old boy die//. Lawyers who are currently handling ... quality of life is so poor and that doctors should ... of the boy and the treating physicians have not been ...
Cached Medicine News:Health News:Vitamin E: good, bad or ugly??? 2Health News:Heart disease: Men Are From Mars, Women From Venus 2Health News:Vitamin E Can Lead To Heart Disease And Cancer 2Health News:Life Or Death: Parents Await High Court Judgment 2
(Date:7/30/2015)... International Inc. (NYSE: MTD ) today announced second ... , Sales in local currency increased 3% ... sales decreased 4% as currency reduced sales growth by ... diluted share as reported (EPS) were $2.73, compared with ... , an increase of 9% over the prior-year ...
(Date:7/30/2015)... , July 30, 2015  Tandem Diabetes ... device company and manufacturer of the t:slim® and ... entered into non-exclusive Development Agreements with Dexcom, Inc. ... insulin pumps with the Dexcom G5 and G6 ... Tandem,s next generation pump platform with Dexcom,s future ...
(Date:7/30/2015)... VANCOUVER , July 30, 2015  OncoGenex ... it will report its second quarter 2015 financial results ... a conference call and live webcast at 4:30 p.m. ... clinical development programs and a general corporate update. ... the Investor Relations page of the OncoGenex website at ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3
... from a pivotal trial suggests that ofatumumab has activity ... , , , ... Genmab A/S (OMX: GEN) announced today positive results from ... in the treatment of refractory chronic lymphocytic leukemia (CLL). ...
... HUNTINGTON BEACH, California and AMSTERDAM, December 8 ,Agendia, ... announced that,leading Agendia and the Netherlands Cancer Institute ... 2008 San Antonio Breast Cancer Symposium,(SABCS) and Agendia ... in Individualized Breast Cancer Therapy symposium. The San ...
Cached Medicine Technology:Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 2Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 3Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 4Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 5Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 6Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 7Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 8Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 9Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium 2Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium 3Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium 4
Facilitates one-lung ventilation when using dual lumen endobronchial tubes....
... Double lumen tubes ... ventilation., ,Each ... is packaged with ... adaptors, suction catheters ...
Used for endobronchial blockade of the left or right lung for procedures which require one-lung ventilation. Supplied sterile in peel-open packages. Intended for one-time use....
The Pedia-Trake® is designed to reduce the possibility of over penetration., ,Pedia-Trake® is used to establish an emergency airway in pediatric patients more than one year old....
Medicine Products: